Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

NCT06292923 is registered in ClinicalTrials.gov with Tiziana Life Sciences LTD as lead sponsor.

NCT NCT06292923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06292923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
Lead sponsor
Tiziana Life Sciences LTD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 15, 2023
Completion date
October 31, 2026
Enrollment
54 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

secondary progressive multiple sclerosis